FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1981246166> ?p ?o ?g. }

• W1981246166 endingPage "288" @default.
• W1981246166 startingPage "280" @default.
• W1981246166 abstract "La globalización y los movimientos migratorios hacen que la hepatitis crónica B Age+ (HCBe+) cobre cada día mayor relevancia en nuestro entorno. Analizar las características epidemiológicas, evolución y respuesta al tratamiento con antivirales orales (AO) de los pacientes con HCBe+. Se analizaron 436 casos de infección crónica por el virus de la hepatitis B atendidos en el Hospital Universitario Ramón y Cajal desde 1990 hasta junio del 2012. Sesenta y cinco (14,9%) presentaban HCBe+. Siete pacientes en fase de tolerancia inmune no fueron tratados; los 58 restantes, sí. Fueron excluidos 4: 2 hepatitis agudas graves, una coinfección por VHC y otro por virus Delta. De los 54 restantes, 19 recibieron interferón con o sin AO y 35 solo AO. Dos tratados durante menos de un mes no fueron incluidos en el análisis. Este se realizó finalmente en 33 pacientes. Duración media del tratamiento: 46,81 meses (6-138). Lamivudina fue el fármaco más prescrito (39,39%), seguida de tenofovir (24,24%) y entecavir (21,21%). Edad media: 42,08 ± 14 años; varones 75,75% (25/33). El 57,57% (19/33) seroconvirtió el antígeno e y el 27,27% (9/33) eliminó el antígeno de superficie. No se objetivó la reaparición de este último tras un seguimiento medio de 35,6 meses. Resistencias: 8 casos en 7 pacientes, 7 a lamivudina y uno a adefovir. El 15% de las HCB en nuestro medio son e+. El tratamiento con AO logra una elevada tasa de seroconversión (57,57%) y un considerable porcentaje de pérdida del antígeno de superficie (27,27%). Due to globalization and migratory movements, HBeAg+ chronic hepatitis B is becoming increasingly important in Spain. To analyze the epidemiological features, progression, and treatment response to oral antiviral agents (OA) in HBeAg+ chronic hepatitis B patients in our area. We analyzed 436 patients with chronic hepatitis B infection followed up at the Ramón y Cajal Hospital from 1990 to June 2012. Sixty-five patients (14.9%) had HBeAg+ chronic hepatitis B. Seven patients in the immunotolerant phase were not treated, while the remaining 58 received treatment. Four patients were excluded: two due to severe acute hepatitis, one due to hepatitis C virus coinfection and another because of a Delta virus coinfection. Of the remaining 54 patients, 19 received interferon with or without OA, and 35 received only OA. Two patients treated for less than 1 month were not included in the analysis. The analysis was finally performed in 33 patients. The mean duration of treatment was 46.81 months (6-138). Lamivudine was the most frequently prescribed drug (39.39%) followed by tenofovir (24.24%) and entecavir (21.21%). The mean age was 42.08 ± 14 years and 75.75% (25/33) of the patients were male. Nineteen of 33 patients (57.57%) achieved seroconversion to anti-HBe, and 27.27% (9/33) showed clearance of HBsAg. There was no evidence of HBsAg reversion after a mean follow-up of 35.6 months. There were 8 cases of resistance in 7 patients: 7 to lamivudine and 1 to adefovir. Approximately 15% of chronic hepatitis B patients in our area are HBeAg+. Treatment with OA achieves a high seroconversion rate (57.57%) and a considerable percentage of HBsAg clearance (27.27%)." @default.
• W1981246166 created "2016-06-24" @default.
• W1981246166 creator A5001192679 @default.
• W1981246166 creator A5019443997 @default.
• W1981246166 creator A5046789127 @default.
• W1981246166 creator A5054601700 @default.
• W1981246166 creator A5059344489 @default.
• W1981246166 creator A5073404261 @default.
• W1981246166 creator A5075394258 @default.
• W1981246166 creator A5084939061 @default.
• W1981246166 date "2014-05-01" @default.
• W1981246166 modified "2023-10-12" @default.
• W1981246166 title "Tratamiento de la hepatitis crónica B antígeno e positiva con antivirales orales: experiencia y resultados en la práctica clínica" @default.
• W1981246166 cites W1545695560 @default.
• W1981246166 cites W1581971337 @default.
• W1981246166 cites W1608280314 @default.
• W1981246166 cites W1815340666 @default.
• W1981246166 cites W1963875503 @default.
• W1981246166 cites W1967677630 @default.
• W1981246166 cites W1985860298 @default.
• W1981246166 cites W1994650227 @default.
• W1981246166 cites W2008517556 @default.
• W1981246166 cites W2009234274 @default.
• W1981246166 cites W2022770725 @default.
• W1981246166 cites W2024593231 @default.
• W1981246166 cites W2026382336 @default.
• W1981246166 cites W2027543203 @default.
• W1981246166 cites W2028885466 @default.
• W1981246166 cites W2039294886 @default.
• W1981246166 cites W2040799770 @default.
• W1981246166 cites W2040989067 @default.
• W1981246166 cites W2042329639 @default.
• W1981246166 cites W2042565956 @default.
• W1981246166 cites W2053396830 @default.
• W1981246166 cites W2055339444 @default.
• W1981246166 cites W2059560167 @default.
• W1981246166 cites W2062680879 @default.
• W1981246166 cites W2063885826 @default.
• W1981246166 cites W2067109440 @default.
• W1981246166 cites W2069395509 @default.
• W1981246166 cites W2076506726 @default.
• W1981246166 cites W2076974448 @default.
• W1981246166 cites W2079006974 @default.
• W1981246166 cites W2084713036 @default.
• W1981246166 cites W2087416757 @default.
• W1981246166 cites W2087564721 @default.
• W1981246166 cites W2090738619 @default.
• W1981246166 cites W2100267258 @default.
• W1981246166 cites W2107889266 @default.
• W1981246166 cites W2108435608 @default.
• W1981246166 cites W2113769724 @default.
• W1981246166 cites W2116578828 @default.
• W1981246166 cites W2133291642 @default.
• W1981246166 cites W2135796667 @default.
• W1981246166 cites W2137544368 @default.
• W1981246166 cites W2142788779 @default.
• W1981246166 cites W2144263253 @default.
• W1981246166 cites W2187843068 @default.
• W1981246166 cites W2328080548 @default.
• W1981246166 cites W2338794667 @default.
• W1981246166 cites W2393327590 @default.
• W1981246166 cites W2460179693 @default.
• W1981246166 cites W3048299720 @default.
• W1981246166 cites W2037600971 @default.
• W1981246166 cites W2146003334 @default.
• W1981246166 cites W2739535516 @default.
• W1981246166 doi "https://doi.org/10.1016/j.gastrohep.2013.11.011" @default.
• W1981246166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24462611" @default.
• W1981246166 hasPublicationYear "2014" @default.
• W1981246166 type Work @default.
• W1981246166 sameAs 1981246166 @default.
• W1981246166 citedByCount "5" @default.
• W1981246166 countsByYear W19812461662015 @default.
• W1981246166 countsByYear W19812461662017 @default.
• W1981246166 countsByYear W19812461662018 @default.
• W1981246166 crossrefType "journal-article" @default.
• W1981246166 hasAuthorship W1981246166A5001192679 @default.
• W1981246166 hasAuthorship W1981246166A5019443997 @default.
• W1981246166 hasAuthorship W1981246166A5046789127 @default.
• W1981246166 hasAuthorship W1981246166A5054601700 @default.
• W1981246166 hasAuthorship W1981246166A5059344489 @default.
• W1981246166 hasAuthorship W1981246166A5073404261 @default.
• W1981246166 hasAuthorship W1981246166A5075394258 @default.
• W1981246166 hasAuthorship W1981246166A5084939061 @default.
• W1981246166 hasConcept C138885662 @default.
• W1981246166 hasConcept C15708023 @default.
• W1981246166 hasConcept C29456083 @default.
• W1981246166 hasConcept C71924100 @default.
• W1981246166 hasConceptScore W1981246166C138885662 @default.
• W1981246166 hasConceptScore W1981246166C15708023 @default.
• W1981246166 hasConceptScore W1981246166C29456083 @default.
• W1981246166 hasConceptScore W1981246166C71924100 @default.
• W1981246166 hasIssue "5" @default.
• W1981246166 hasLocation W19812461661 @default.
• W1981246166 hasLocation W19812461662 @default.
• W1981246166 hasOpenAccess W1981246166 @default.
• W1981246166 hasPrimaryLocation W19812461661 @default.
• W1981246166 hasRelatedWork W1506200166 @default.

• next